Drug intelligence / Profile preview

sitagliptin + BeiDouGen

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

Sitagliptin + BeiDouGen is a combination therapy under investigation for the treatment of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that works by increasing incretin levels, which in turn increases insulin secretion and decreases glucagon secretion, leading to improved glycemic control. BeiDouGen appears to refer to a capsule formulation used in China, but its precise composition and mechanism are not well characterized in English-language sources; it may be an herbal or traditional medicine adjunct. The combination aims to enhance glycemic control beyond what is achieved with sitagliptin alone[1].

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on sitagliptin + BeiDouGen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sitagliptin + BeiDouGen.

Explore the full profile